| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1010202150 |
| P356 | DOI | 10.1038/SJ.BMT.1705454 |
| P698 | PubMed publication ID | 16951692 |
| P5875 | ResearchGate publication ID | 6837676 |
| P50 | author | Inken Hilgendorf | Q73734464 |
| P2093 | author name string | Freund M | |
| Wolff D | |||
| Hartung G | |||
| Holler E | |||
| Wilhelm S | |||
| Steiner B | |||
| Gentilini C | |||
| Uharek L | |||
| Casper J | |||
| Hahn J | |||
| Junghanss C | |||
| Kahl C | |||
| P2860 | cites work | Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: the role of von Willebrand factor-cleaving protease | Q28202805 |
| Use of daclizumab as initial immunosuppression in liver transplant recipients with impaired renal function | Q32186712 | ||
| Treatment of steroid-resistant acute graft-versus-host disease with daclizumab and etanercept | Q33213561 | ||
| Defibrotide in recurrent thrombotic thrombocytopenic purpura | Q33332186 | ||
| Impact of thrombotic thrombocytopenic purpura on leukemic children undergoing bone marrow transplantation | Q33335309 | ||
| The clinical features, risk factors and outcome of thrombotic thrombocytopenic purpura occurring after bone marrow transplantation. | Q33337105 | ||
| BMT: Bone Marrow Transplant Associated Thrombotic Microangiopathy | Q33337686 | ||
| Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease | Q33340454 | ||
| Questionable efficacy of plasma exchange for thrombotic thrombocytopenic purpura after bone marrow transplantation | Q33340968 | ||
| Von Willebrand factor-cleaving protease activity and proteolysis of von Willebrand factor in bone marrow transplant-associated thrombotic microangiopathy | Q33341756 | ||
| Thrombotic thrombocytopenic purpura after allogeneic stem cell transplantation: a survey of the European Group for Blood and Marrow Transplantation (EBMT). | Q33343954 | ||
| Transplantation-associated thrombotic microangiopathy is associated with transplantation from unrelated donors, acute graft-versus-host disease and venoocclusive disease of the liver | Q33344003 | ||
| Thrombotic thrombocytopenic purpura following stem cell transplantation | Q33345682 | ||
| Clinical significance of fragmented red cells after allogeneic bone marrow transplantation | Q33346861 | ||
| Posttransplantation thrombotic thrombocytopenic purpura: a single-center experience and a contemporary review | Q33347394 | ||
| Thrombotic microangiopathy after allogeneic blood and marrow transplantation is associated with dose-intensive myeloablative conditioning regimens, unrelated donor, and methylprednisolone T-cell depletion | Q33364155 | ||
| Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation | Q33367451 | ||
| Plasma exchange and vincristine in the treatment of hemolytic uremic syndrome/thrombotic thrombocytopenic purpura associated with bone marrow transplantation | Q33389471 | ||
| Selective inhibition of vascular endothelial growth factor-mediated angiogenesis by cyclosporin A: roles of the nuclear factor of activated T cells and cyclooxygenase 2 | Q36369190 | ||
| Fludarabine induces apoptosis, activation, and allogenicity in human endothelial and epithelial cells: protective effect of defibrotide | Q44031721 | ||
| Renal dysfunction in allogeneic hematopoietic cell transplantation | Q44057573 | ||
| Treatment of steroid refractory acute and chronic graft-versus-host disease with daclizumab | Q44092412 | ||
| Circulating endothelial cells are a novel marker of cyclosporine-induced endothelial damage | Q44353827 | ||
| Role of Endothelin-1 in Microvascular Dysfunction Caused by Cyclosporin A | Q44401130 | ||
| Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial | Q44892383 | ||
| Acute renal failure after myeloablative hematopoietic cell transplant: incidence and risk factors | Q45195087 | ||
| Influence of bacterial endotoxin on the allogenicity of human endothelial cells | Q61893859 | ||
| Acute renal failure following bone marrow transplantation: a retrospective study of 272 patients | Q69486724 | ||
| Cyclosporine-induced detachment of vascular endothelial cells initiates the intrinsic coagulation system in plasma and whole blood | Q71120916 | ||
| Treatment of thrombotic thrombocytopenic purpura with defibrotid | Q72796058 | ||
| Daclizumab (Zenapax) inhibits early interleukin-2 receptor signal transduction events | Q73370304 | ||
| Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use study | Q73416359 | ||
| Endothelial injury mediated by cytotoxic T lymphocytes and loss of microvessels in chronic graft versus host disease | Q74372364 | ||
| Acute renal failure following bone marrow transplantation | Q74600272 | ||
| Renal failure and bone marrow transplantation | Q77484534 | ||
| Defibrotide as a promising treatment for thrombotic thrombocytopenic purpura in patients undergoing bone marrow transplantation | Q77962021 | ||
| Combining altered levels of effector transcripts in circulating T cells with a marker of endothelial injury is specific for active graft-versus-host disease | Q79305214 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 445-451 | |
| P577 | publication date | 2006-09-01 | |
| P1433 | published in | Bone Marrow Transplantation | Q4941523 |
| P1476 | title | Replacement of calcineurin inhibitors with daclizumab in patients with transplantation-associated microangiopathy or renal insufficiency associated with graft-versus-host disease | |
| P478 | volume | 38 |
| Q36759581 | Advances in the understanding of acute graft-versus-host disease. |
| Q33375739 | Diagnosis and treatment of transplantation-associated thrombotic microangiopathy: real progress or are we still waiting? |
| Q34522746 | Emergent Complications in the Pediatric Hematopoietic Stem Cell Transplant Patient |
| Q33424902 | Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy |
| Q41992358 | Hematopoietic stem cell transplant-associated thrombotic microangiopathy: current paradigm and novel therapies. |
| Q89891758 | Incidence and Mortality of Acute Kidney Injury in Patients Undergoing Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-analysis |
| Q38806679 | Is complement blockade an acceptable therapeutic strategy for hematopoietic cell transplant-associated thrombotic microangiopathy? |
| Q79773981 | Nitric oxide in transplantation-related thrombotic microangiopathy |
| Q36294351 | Onco-nephrology: AKI in the cancer patient |
| Q33417690 | Outcomes of plasma exchange in patients with transplant-associated thrombotic microangiopathy based on time of presentation since transplant |
| Q34316381 | Remission of microangiopathy in transplanted thalassemic child |
| Q38944989 | Renal dysfunction following bone marrow transplantation |
| Q36445665 | Single-Agent Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis after Human Leukocyte Antigen-Matched Related Bone Marrow Transplantation for Pediatric and Young Adult Patients with Hematologic Malignancies |
| Q38287610 | Therapeutic apheresis for patients with cancer |
| Q35098992 | Thrombotic microangiopathy in haematopoietic cell transplantation: an update |
| Q33383355 | Thrombotic microangiopathy in haematopoietic stem cell transplantation: diagnosis and treatment |
| Q64063450 | Transplant-Associated Thrombotic Microangiopathy in Pediatric Hematopoietic Cell Transplant Recipients: A Practical Approach to Diagnosis and Management |
| Q30235311 | Transplant-associated thrombotic microangiopathy: opening Pandora's box. |
Search more.